We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Hemorrhagic Fever Viruses Could Be Bioweapons

By Biotechdaily staff writers
Posted on 27 May 2002
Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa could be used as biologic weapons, according to a report from a panel of experts convened by the Center for Civilian Biodefense Strategies at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA). More...
The panel's consensus statement was published in the May 8, 2002, issue of the Journal of the American Medical Association (JAMA).

Hemorrhagic fever viruses are considered "Category A” biologic weapons agents by the US Centers for Disease Control and Prevention (CDC) because they have the potential to cause widespread illness and death. The panel's report focused on eight viruses: Ebola, Marburg, Lassa fever, New World Arenavirus, Rift Valley fever, yellow fever, Ornsk hemorrhagic fever, and Kyasanur Forest disease. Ebola and Marburg are among the most deadly of these. Ebola kills 50-90% of those infected, and Marburg is fatal in 23-70% of cases.

There are no widely available diagnostic tests for these viruses, and few effective therapies or vaccines are available to treat them. The panel says strict infection controls need to be used during an outbreak, since many of the viruses can be spread by person-to-person contact. Patients should be isolated, and clinicians should wear protective gear.

"The Working Group's consensus recommends improvement to our diagnostic capacity and the development of a rapid test for diagnosing hemorrhagic fever viruses,” said Luciana Borio, M.D., lead author and a fellow at the Hopkins Center for Civilian Biodefense Strategies. "Research efforts should also focus on new antiviral medications, vaccines, and a more fundamental scientific study of the viruses that cause hemorrhagic illness.”




Related Links:
Center for Civilian Biodefense
JAMA

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.